Advertisement.

IMTX Projected Dividend Yield

Ord/Immatics NV ( NASDAQ : IMTX )

Immatics is a holding company. Through its subsidiaries, Co. is engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer patients. Co.'s focus is the generation of therapeutic options for solid tumor patients. Co. is developing its targeted immunotherapy product candidates via two treatment modalities: Adoptive Cell Therapies (ACT) and antibody-like Bispecifics. Co.'s clinical product class ACTengine is based on genetically modifying a patient's own T cells to express a proprietary TCR. Co.'s TCR Bispecifics are consisting of a portion of the TCR that recognizes cancer cells and a T cell recruiter domain that recruits and activates T cells.

20 YEAR PERFORMANCE RESULTS

IMTX Dividend History Detail
IMTX Dividend News
IMTX Competitors News

# of Shares: 0

Closing Price: 7.21

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000